Skip to content
PubMed This is a summary of 7 peer-reviewed journal articles Updated
Oncology

Can You Live With Follicular Lymphoma Without Treatment?

At a Glance

Yes, roughly 15% to 20% of patients with slow-growing, low-burden follicular lymphoma may live for decades and never require treatment. Because early intervention does not improve overall survival, doctors use 'watch and wait' to safely delay therapy until symptoms appear.

Yes, it is possible. While follicular lymphoma is a type of blood cancer, intervention is not always an absolute certainty for everyone. If your care team has recommended “watch and wait” (also called active surveillance), it means your disease is slow-growing, asymptomatic, and low-burden (meaning the swollen lymph nodes are relatively small, few in number, and not interfering with your major organs) [1]. While most people will eventually need therapy, a significant minority—roughly 15% to 20% of patients—may live for decades and never require treatment [2].

What Do the Long-Term Statistics Show?

The uncertainty of waiting can be frightening, but looking at long-term data can offer some clarity. Over decades of observation, researchers have tracked how long patients can safely go without treatment:

  • Median time to first treatment: For patients on watch and wait, the median time before needing treatment is generally around 2.5 to 3 years [3][4].
  • At 10 years: Depending on the study group, between 19% and 35% of patients remain completely treatment-free at the 10-year mark [3][5].
  • At 15 to 20 years: Long-term studies show that in some low-risk groups, up to 34% of patients are still treatment-free at 15 years [2].

Interestingly, if you remain stable for the first few years without progression, your likelihood of needing treatment in the immediate future often decreases. Today, with modern medical advances, the median survival time for follicular lymphoma reaches 18 to 20 years, and many patients live out their normal lifespans [6][7].

Spontaneous Regression

It may be surprising to learn that follicular lymphoma is one of the few cancers that can actually shrink on its own. Roughly 23% of patients on active surveillance will experience a spontaneous regression [3]. This means that the enlarged lymph nodes shrink or disappear without any medical intervention. However, because follicular lymphoma is characterized by a relapsing and remitting course, these regressions are usually temporary. The nodes may grow back over time, but a regression can significantly delay the time before treatment is ever needed.

Why Not Treat Early “Just in Case”?

It is entirely normal to wonder why your doctor wouldn’t want to treat the cancer right away to stop it from growing. Decades of research and multiple clinical trials have confirmed that starting treatment before you have symptoms does not improve your overall survival [1]. In other words, treating early does not help you live longer; it only exposes you to the unnecessary side effects of chemotherapy or targeted therapies earlier than needed.

What to Expect During Watch and Wait

While the watch-and-wait strategy is safe and standard, it is not “watch and ignore.” You will have regular check-ups to monitor your condition, typically every 3 to 6 months. These visits usually involve a physical exam to check your lymph nodes, routine blood work, and occasionally imaging (like CT scans) if your doctor suspects changes.

The main risk your doctor will look out for over the long term is histological transformation [5]. This is when the slow-growing lymphoma changes into a faster-growing, more aggressive type of lymphoma. This happens in about 22% of watch-and-wait patients by the 10-year mark [5]. While this sounds alarming, transformed lymphoma is actively treatable with different, more intensive therapies.

Because of the risk of progression or transformation, it is important to contact your doctor if you notice any new or worsening symptoms between your scheduled visits, such as:

  • Sudden, drenching night sweats
  • Unexplained, significant weight loss
  • Persistent fevers
  • Rapidly growing lymph nodes

In the meantime, focusing on general wellness—such as eating a balanced diet, staying active, and managing stress—can help you feel your best and give you a sense of control during active surveillance.

Common questions in this guide

Can you live with follicular lymphoma without ever getting treatment?
Yes, roughly 15% to 20% of patients with slow-growing, low-burden follicular lymphoma may live for decades without ever requiring treatment. Most patients, however, will eventually need therapy after a period of active surveillance.
Why do doctors recommend watch and wait instead of treating follicular lymphoma early?
Decades of clinical trials show that starting treatment before you have symptoms does not improve overall survival. Treating early only exposes patients to unnecessary side effects from chemotherapy or targeted therapies earlier than needed.
Can follicular lymphoma shrink on its own?
Yes, about 23% of patients on active surveillance experience a spontaneous regression, where enlarged lymph nodes shrink without medical intervention. However, because follicular lymphoma is a relapsing disease, these regressions are usually temporary.
What signs mean my follicular lymphoma might need treatment?
You should contact your care team if you notice sudden drenching night sweats, unexplained significant weight loss, persistent fevers, or rapidly growing lymph nodes between your regular check-ups.
What is histological transformation in follicular lymphoma?
Histological transformation happens when slow-growing follicular lymphoma changes into a faster-growing, more aggressive type of lymphoma. This occurs in about 22% of watch-and-wait patients by the 10-year mark and requires more intensive treatment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my initial scans and blood work, am I considered to have a 'low tumor burden'?
  2. 2.How often will we schedule monitoring appointments, and will those visits involve physical exams, blood tests, or imaging like CT scans?
  3. 3.What specific signs or symptoms should prompt me to call your office before my next scheduled check-up?
  4. 4.If my lymph nodes begin to grow, how much growth is needed before you would recommend starting treatment?
  5. 5.Do my biopsy results show any specific features that might make my lymphoma more likely to need treatment sooner rather than later?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (7)
  1. 1

    Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.

    Arushi Khurana , Mwangi R, Ansell SM, et al.

    Blood cancer journal 2021; (11(7)):133 doi:10.1038/s41408-021-00525-0.

    PMID: 34274939
  2. 2

    Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial.

    Northend M, Wilson W, Ediriwickrema K, et al.

    The Lancet. Haematology 2025; (12(5)):e335-e345 doi:10.1016/S2352-3026(25)00034-1.

    PMID: 40306831
  3. 3

    The natural history of initially untreated low-grade non-Hodgkin's lymphomas.

    Horning SJ, Rosenberg SA

    The New England journal of medicine 1984; (311(23)):1471-5 doi:10.1056/NEJM198412063112303.

    PMID: 6548796
  4. 4

    Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

    Ardeshna KM, Qian W, Smith P, et al.

    The Lancet. Oncology 2014; (15(4)):424-35.

    PMID: 24602760
  5. 5

    A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.

    El-Galaly TC, Bilgrau AE, de Nully Brown P, et al.

    British journal of haematology 2015; (169(3)):435-44 doi:10.1111/bjh.13316.

    PMID: 25709094
  6. 6

    Mosunetuzumab for the treatment of follicular lymphoma.

    Labanca C, Martino EA, Vigna E, et al.

    Expert opinion on biological therapy 2024; (24(10)):1039-1048 doi:10.1080/14712598.2024.2404079.

    PMID: 39259182
  7. 7

    Time for an individualized approach to first-line management of follicular lymphoma.

    Cartron G, Trotman J

    Haematologica 2022; (107(1)):7-18 doi:10.3324/haematol.2021.278766.

    PMID: 34985230

This information about follicular lymphoma active surveillance is for educational purposes only. Always consult your oncologist to determine the safest monitoring and treatment strategy for your specific diagnosis.

Get notified when new evidence is published on Follicular lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.